000124405 001__ 124405
000124405 005__ 20240228145512.0
000124405 0247_ $$2doi$$a10.18632/oncotarget.14004
000124405 0247_ $$2pmid$$apmid:28002790
000124405 0247_ $$2pmc$$apmc:PMC5355278
000124405 037__ $$aDKFZ-2017-01284
000124405 041__ $$aeng
000124405 082__ $$a610
000124405 1001_ $$0P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aSelt, Florian$$b0$$eFirst author
000124405 245__ $$aEstablishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
000124405 260__ $$a[S.l.]$$bImpact Journals LLC$$c2017
000124405 3367_ $$2DRIVER$$aarticle
000124405 3367_ $$2DataCite$$aOutput Types/Journal article
000124405 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1533281046_32711
000124405 3367_ $$2BibTeX$$aARTICLE
000124405 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124405 3367_ $$00$$2EndNote$$aJournal Article
000124405 520__ $$aPilocytic astrocytoma (PA) is the most frequent pediatric brain tumor. Activation of the MAPK pathway is well established as the oncogenic driver of the disease. It is most frequently caused by KIAA1549:BRAF fusions, and leads to oncogene induced senescence (OIS). OIS is thought to be a major reason for growth arrest of PA cells in vitro and in vivo, preventing establishment of PA cultures. Hence, valid preclinical models are currently very limited, but preclinical testing of new compounds is urgently needed. We transduced the PA short-term culture DKFZ-BT66 derived from the PA of a 2-year old patient with a doxycycline-inducible system coding for Simian Vacuolating Virus 40 Large T Antigen (SV40-TAg). SV40-TAg inhibits TP53/CDKN1A and CDKN2A/RB1, two pathways critical for OIS induction and maintenance. DNA methylation array and KIAA1549:BRAF fusion analysis confirmed pilocytic astrocytoma identity of DKFZ-BT66 cells after establishment. Readouts were analyzed in proliferating as well as senescent states, including cell counts, viability, cell cycle analysis, expression of SV40-Tag, CDKN2A (p16), CDKN1A (p21), and TP53 (p53) protein, and gene-expression profiling. Selected MAPK inhibitors (MAPKi) including clinically available MEK inhibitors (MEKi) were tested in vitro. Expression of SV40-TAg enabled the cells to bypass OIS and to resume proliferation with a mean doubling time of 45h allowing for propagation and long-term culture. Withdrawal of doxycycline led to an immediate decrease of SV40-TAg expression, appearance of senescent morphology, upregulation of CDKI proteins and a subsequent G1 growth arrest in line with the re-induction of senescence. DKFZ-BT66 cells still underwent replicative senescence that was overcome by TERT expression. Testing of a set of MAPKi revealed differential responses in DKFZ-BT66. MEKi efficiently inhibited MAPK signaling at clinically achievable concentrations, while BRAF V600E- and RAF Type II inhibitors showed paradoxical activation. Taken together, we have established the first patient-derived long term expandable PA cell line expressing the KIAA1549:BRAF-fusion suitable for preclinical drug testing.
000124405 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000124405 588__ $$aDataset connected to CrossRef, PubMed,
000124405 7001_ $$0P:(DE-He78)70be585796dc36458712b89a0dcb54a7$$aHohloch, Juliane$$b1
000124405 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b2
000124405 7001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b3
000124405 7001_ $$0P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aCapper, David$$b4
000124405 7001_ $$0P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aKorshunov, Andrey$$b5
000124405 7001_ $$0P:(DE-He78)7d5cd95cbedad26188a1df9eeca335ef$$aUsta, Diren$$b6
000124405 7001_ $$0P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aBrabetz, Sebastian$$b7
000124405 7001_ $$0P:(DE-He78)53112ef656923758316e7079710bc988$$aRidinger, Johannes$$b8
000124405 7001_ $$0P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aEcker, Jonas$$b9
000124405 7001_ $$0P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aOehme, Ina$$b10
000124405 7001_ $$0P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d$$aGronych, Jan$$b11
000124405 7001_ $$0P:(DE-He78)da540cf439735fb1385a3a90933baa23$$aMarquardt, Viktoria$$b12$$udkfz
000124405 7001_ $$0P:(DE-He78)964e19ad88fd6ff751ae2c10599ad7cc$$aPauck, David$$b13$$udkfz
000124405 7001_ $$aBächli, Heidi$$b14
000124405 7001_ $$aStiles, Charles D$$b15
000124405 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b16
000124405 7001_ $$0P:(DE-He78)a244aa021112b9002419791434bbc71c$$aRemke, Marc$$b17$$udkfz
000124405 7001_ $$aSchuhmann, Martin U$$b18
000124405 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan$$b19
000124405 7001_ $$aBrummer, Tilman$$b20
000124405 7001_ $$0P:(DE-He78)551bb92841f634070997aa168d818492$$aJones, David$$b21
000124405 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b22
000124405 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b23$$eLast author
000124405 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.14004$$gVol. 8, no. 7$$n7$$p11460-11479$$tOncoTarget$$v8$$x1949-2553$$y2017
000124405 909CO $$ooai:inrepo02.dkfz.de:124405$$pVDB
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a23e88cc676489fe05be8c178ceaf58e$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)70be585796dc36458712b89a0dcb54a7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)51bf9ae9cb5771b30c483e5597ef606c$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d5cd95cbedad26188a1df9eeca335ef$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b0b3740107f746e09dc23fdf25eb0629$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)53112ef656923758316e7079710bc988$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3de637452ba900e2bdd359b8f41953bf$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)908367a659dea9e28dac34592b3c46e5$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bb186a8b38fef24ebd6f11918ade985d$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)da540cf439735fb1385a3a90933baa23$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)964e19ad88fd6ff751ae2c10599ad7cc$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b16$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a244aa021112b9002419791434bbc71c$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)551bb92841f634070997aa168d818492$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b22$$kDKFZ
000124405 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b23$$kDKFZ
000124405 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000124405 9141_ $$y2017
000124405 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000124405 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124405 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124405 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000124405 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124405 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124405 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124405 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000124405 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000124405 9201_ $$0I:(DE-He78)G340-20160331$$kG340$$lKKE Pädiatrische Onkologie$$x0
000124405 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000124405 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x2
000124405 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x3
000124405 9201_ $$0I:(DE-He78)B060-20160331$$kB060$$lMolekulare Genetik$$x4
000124405 9201_ $$0I:(DE-He78)L401-20160331$$kL401$$lDKTK Essen$$x5
000124405 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x6
000124405 9201_ $$0I:(DE-He78)L601-20160331$$kL601$$lDKTK Freiburg$$x7
000124405 980__ $$ajournal
000124405 980__ $$aVDB
000124405 980__ $$aI:(DE-He78)G340-20160331
000124405 980__ $$aI:(DE-He78)C060-20160331
000124405 980__ $$aI:(DE-He78)G380-20160331
000124405 980__ $$aI:(DE-He78)B062-20160331
000124405 980__ $$aI:(DE-He78)B060-20160331
000124405 980__ $$aI:(DE-He78)L401-20160331
000124405 980__ $$aI:(DE-He78)L101-20160331
000124405 980__ $$aI:(DE-He78)L601-20160331
000124405 980__ $$aUNRESTRICTED